Title : An Isoflavonoid Modulator of Oxidative Metabolism with Therapeutic Potential in Obesity and Diabetes (WE-868) Date and Time : Tuesday, November 4, 2025 at 7:30 p.m. - 8:30 p.m. ET Presenter : ...
Because GLP-1 agonists seem to reduce patients’ desire for food, it isn’t surprising that they might also shrink or even ...
A small study found that drugs like Ozempic, Wegovy, and Mounjaro change the way the body processes alcohol, making it less ...
Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse eventsAsymptomatic, reversible grade ...
16h
Michigan to limit Medicaid coverage for weight loss drugs to people with diabetes, morbid obesity
Michigan lawmakers plan to save money in the state's Medicaid program by limiting the use of popular weight loss drugs to ...
ORLANDO -- Adding another twist to the ongoing debate about the effects of weight-loss drugs on vision, a retrospective ...
Revolutionary progress, like that of GLP-1 drugs, happens when many exceptional people work together, following a robust ...
Plus: Everything you need to know about Philly's newest food hall, River Twice announces "7 Deadly Sins" dinner, and Cider ...
This Stony Brook University-based study reviewed how sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like ...
A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.
Cosmo Fowler, M.D., from Emory University in Atlanta, and colleagues examined data from the TriNetX U.S. Collaborative Network to examine whether OSA modifies outcomes in patients with T2DM receiving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback